Similar results were obtained in two other BRCA2 monoallelic and biallelic mutant tumor xenograft models (p < 0.01, Fig. 3k and m upper), and significantly improved survival rates for the MMC-treated mice compared with the control mice (p < 0.01, Fig. 3k and m bottom). This evidence concerns the gene BRCA2 and neoplasm.